Cargando…
Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
INTRODUCTION: Short‐course preventive therapy with 1‐month course of daily administration of isoniazid (300‐mg) plus rifapentine (600‐mg) (1HP) and 3‐month course of weekly administration of isoniazid (900‐mg) plus rifapentine (900‐mg) (3HP) has higher completion rates than 9‐month course of daily i...
Autores principales: | Liou, Bo‐Huang, Cheng, Chih‐Ning, Lin, Ya‐Ting, Lin, Yu‐Jou, Chuang, Yu‐Chung, Lin, Kuan‐Yin, Liu, Wen‐Chun, Lin, Shu‐Wen, Kuo, Ching‐Hua, Sun, Hsin‐Yun, Hung, Chien‐Ching |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614225/ https://www.ncbi.nlm.nih.gov/pubmed/34822220 http://dx.doi.org/10.1002/jia2.25844 |
Ejemplares similares
-
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018) -
Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV
por: Chen, I-Wen, et al.
Publicado: (2021) -
Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023) -
Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey
por: Balcı, Umay, et al.
Publicado: (2023) -
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
por: Deeks, Emma D.
Publicado: (2018)